| Document Date: 2014-11-03 11:26:22
Open Document File Size: 66,50 KBShare Result on Facebook
City Osaka / Vienna / / Company Pfizer / GlaxoSmithKline / ABC / HIV/AIDS / Shionogi & Co. Ltd. / ViiV Healthcare / Shionogi-ViiV Healthcare LLC / Japan Shionogi & Co. / Shionogi Inc. / / Country Austria / / Event FDA Phase / / IndustryTerm in-line products / pharmaceutical / foreign healthcare reforms / with respect to product / / MedicalCondition insomnia / cancer / HIV / allergy / Metabolic Syndrome / AIDS / Infectious Diseases / rash / / Organization Federal Trade Commission / / Person Tsutae "Den" Nagata / John Pottage / David Mawdsley / Rebecca Hunt / Marc Meachem / / / Position Chief Medical Officer / Medical Officer / Analyst / Private / Chief / / Product efavirenz / abacavir / lamivudine / GSK1265744 / MOAB0105 / SPRING-1 / GSK1349572 / / Technology genotype / / URL www.shionogi.co.jp / www.shionogi-inc.com / www.viivhealthcare.com / /
SocialTag |
Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S